Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With... Key PointsQuestionDoes administration of adjuvant imatinib for 3 years after macroscopically complete surgery prolong overall survival (OS) compared with 1-year administration in patients with localized gastrointestinal stromal tumor (GIST) with high-risk features? FindingsThis secondary analysis of a randomized clinical trial of 397 patients with high-risk GIST found that, after a median follow-up time of 10 years after the study entry, patients randomly allocated to receive 3 years of imatinib had longer recurrence-free survival and OS than patients allocated to 1 year of imatinib: Approximately one-half of deaths were avoided with the longer treatment. No new adverse safety signals were detected. MeaningThree years of treatment with adjuvant imatinib was associated with improved OS compared with 1 year of imatinib in patients with high-risk GIST. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/survival-outcomes-associated-with-3-years-vs-1-year-of-adjuvant-pkuCDW61bH

References (17)

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.2091
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionDoes administration of adjuvant imatinib for 3 years after macroscopically complete surgery prolong overall survival (OS) compared with 1-year administration in patients with localized gastrointestinal stromal tumor (GIST) with high-risk features? FindingsThis secondary analysis of a randomized clinical trial of 397 patients with high-risk GIST found that, after a median follow-up time of 10 years after the study entry, patients randomly allocated to receive 3 years of imatinib had longer recurrence-free survival and OS than patients allocated to 1 year of imatinib: Approximately one-half of deaths were avoided with the longer treatment. No new adverse safety signals were detected. MeaningThree years of treatment with adjuvant imatinib was associated with improved OS compared with 1 year of imatinib in patients with high-risk GIST.

Journal

JAMA OncologyAmerican Medical Association

Published: Aug 29, 2020

There are no references for this article.